original without the text.png
iStock_000007245036Medium.jpg
shutterstock_193463279.jpg
original without the text.png

Genostics


The future of personalised cancer testing, today.

SCROLL DOWN

Genostics


The future of personalised cancer testing, today.

Genostics® is an Australian medical diagnostic, education and consultancy company.

In this video, Dr. Joachim Fluhrer and Prof. Katherina Pachmann discuss Circulating Tumour Cells: what they are, their importance, and how to detect them.

Genostics® partners with world-class cancer research laboratories in Europe to bring the very best in personalised cancer testing to the Australian and New Zealand medical communities.

We engage with pioneering practitioners who seek to discover the exact nature of each patient's cancer. These practitioners use Genostics® tests to help design personalised treatment plans and to closely monitor the effectiveness of therapies.

Specialising in the field of Oncology, we are proud to be bringing the future of personalised caner testing to patients, today


 
iStock_000007245036Medium.jpg

Patient information


SCROLL DOWN

Patient information


Every person's cancer is unique.

A growing tumour is made up of many different cancer cells. If a cancer is malignant, a select population of cancer cells can escape the tumour mass and invade the blood stream. When this happens, the cancer is at a turning point. Escapee cancer cells in the blood stream can travel to another site in the body and grow a second tumour at a later stage, called a metastasis. These escapee cancer cells in the blood are called Circulating Tumour Cells, abbreviated as ‘CTCs.’


Escapee cancer cells in the blood can be found by a simple blood test.

A CTC Count finds existing escapee CTCs in a blood sample and counts them. A CTC count every 3-6 months can be used to monitor the effectiveness of cancer treatment and assess changes in aggressiveness. This test is the best way of closely monitoring the status of a person's cancer.

A CTC Count finds existing escapee CTCs in a blood sample and counts them. A CTC count every 3-6 months can be used to monitor the effectiveness of cancer treatment and assess changes in aggressiveness. This test is the best way of closely monitoring the status of a person's cancer.

This test exposes a person's CTCs to recommended chemotherapy or botanical cancer killing agents, as selected by healthcare practitioners. This test is to see which therapy or therapy combination is most effective at killing a person's CTCs. CTCs that survive exposure are said to be resistant while CTCs that are killed by exposure are said to be sensitive. Cancer treatment can then be tailored to target the cells that are responsible for cancer spread.

This test exposes a person's CTCs to recommended chemotherapy or botanical cancer killing agents, as selected by healthcare practitioners. This test is to see which therapy or therapy combination is most effective at killing a person's CTCs. CTCs that survive exposure are said to be resistant while CTCs that are killed by exposure are said to be sensitive. Cancer treatment can then be tailored to target the cells that are responsible for cancer spread.

Companion Diagnostics identifies the presence of receptors on a person's CTCs that may be specifically targeted by certain cancer treatments. Practitioners can also choose to test for other 'biomarkers' that indicate important factors, such as aggression and activity. This test helps practitioners select treatments to target the unique nature of each person's cancer.

Companion Diagnostics identifies the presence of receptors on a person's CTCs that may be specifically targeted by certain cancer treatments. Practitioners can also choose to test for other 'biomarkers' that indicate important factors, such as aggression and activity. This test helps practitioners select treatments to target the unique nature of each person's cancer.

Customised Combination test is a comprehensive evaluation of a person's CTCs and includes the CTC Count, Customised Chemosensitivity and Companion Diagnostics tests. Practitioners tailor each test to gain a thorough understanding of the unique genetics and behaviour of a person's cancer. Results may assist in optimising outcomes in a personalised treatment plan.

Customised Combination test is a comprehensive evaluation of a person's CTCs and includes the CTC Count, Customised Chemosensitivity and Companion Diagnostics tests. Practitioners tailor each test to gain a thorough understanding of the unique genetics and behaviour of a person's cancer. Results may assist in optimising outcomes in a personalised treatment plan.

Acute Treatment Response is a series of 2-3 CTC counts taken before, during and after chemotherapy treatment. The series is taken within a three-month period. This test closely inspects the immediate response of your CTCs to chemotherapy or other cancer treatment.

Acute Treatment Response is a series of 2-3 CTC counts taken before, during and after chemotherapy treatment. The series is taken within a three-month period. This test closely inspects the immediate response of your CTCs to chemotherapy or other cancer treatment.

Tumour Sphere Units tests to see if a person's CTCS can multiply to form microscopic clusters, called Tumour Sphere Units in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis.

Tumour Sphere Units tests to see if a person's CTCS can multiply to form microscopic clusters, called Tumour Sphere Units in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis.


 
shutterstock_193463279.jpg

Practitioner information


SCROLL DOWN

Practitioner information


The effectiveness of cancer therapy can now be monitored

"There is increasing evidence that CTCs reflect cancer progression in real time and that this information may be particularly helpful in the context of systemic therapies. In the future, CTC characterisation is expected to contribute to guiding specific targeted therapies to a defined population of cancer patients within a certain therapeutic window...

- which is the hallmark of personalized medicine." - Clin Chem 2012